A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplants
CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO® to prevent fungal infections in stem-cell transplant patients, granting Priority Review with a Q1 2027 target action date. The application is based on the Phase III ReSPECT study, which showed positive results in April. If approved, CorMedix plans to begin promotional efforts in H2 2027.
How this was made
The 30-second read
Why it matters
The filing adds a significant regulatory catalyst that could materially affect CRMD's valuation and pipeline perception.
Market read
Regulatory progress for a late‑stage drug candidate often drives biotech stock moves; investors will watch the Q1 2027 PDUFA deadline.
What to watch
Potential competition from other echinocandins and the need for reimbursement approvals.
Background
CorMedix Therapeutics announced FDA acceptance of its supplemental NDA for rezafungin prophylaxis, a new indication beyond its current candidemia approval.
Ticker impact
FDA accepted CorMedix's supplemental NDA for rezafungin, granting Priority Review with a Q1 2027 action date.
upward pressure as market anticipates future approval and revenue uplift
Regulatory milestone for a late‑stage antifungal; biotech stocks typically rally on FDA priority review.
Market effects
Strengthens outlook for the antifungal and broader infectious‑disease therapeutic sector.
U.S. biotech market may see modest gains as investors re‑price similar pipeline candidates.
Limited to biotech investors; no broad market impact.
Counterpoint
If the FDA later requests additional data, the stock could face a sharp correction.
Key entities
- CompanyCorMedix Therapeutics
Biopharma developing rezafungin and other antifungal therapies.
- CompanyMundipharma
Global development partner collaborating on the rezafungin sNDA.
